Pub Date : 2022-12-13DOI: 10.19080/jocct.2022.18.555977
B. Ivanović
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of medications used for the treatment of diabetes mellitus (DM). It has been shown that, in addition to a favorable metabolic effect, they significantly reduce atherosclerotic events, cardiovascular and total mortality, hospitalization duration in patients with heart failure and have a significant effect on reducing the progression of chronic kidney disease. It has been observed that in patients with diabetes mellitus, they lead to a reduction of blood pressure (BP). The aim of this article is to evaluate current knowledge about mechanisms of antihypertensive action and clinical benefits of SGLT2 inhibitors in reducing arterial blood pressure in patients with diabetes mellitus and arterial hypertension.
{"title":"SGLT 2 Inhibitors and Hypertension: Mild but Effective. What can we expect ?","authors":"B. Ivanović","doi":"10.19080/jocct.2022.18.555977","DOIUrl":"https://doi.org/10.19080/jocct.2022.18.555977","url":null,"abstract":"Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new class of medications used for the treatment of diabetes mellitus (DM). It has been shown that, in addition to a favorable metabolic effect, they significantly reduce atherosclerotic events, cardiovascular and total mortality, hospitalization duration in patients with heart failure and have a significant effect on reducing the progression of chronic kidney disease. It has been observed that in patients with diabetes mellitus, they lead to a reduction of blood pressure (BP). The aim of this article is to evaluate current knowledge about mechanisms of antihypertensive action and clinical benefits of SGLT2 inhibitors in reducing arterial blood pressure in patients with diabetes mellitus and arterial hypertension.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122372940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-12DOI: 10.19080/jocct.2022.18.555976
Maria Isabel Gomez Coral
Tuberculous pericarditis is produced by Mycobacterium tuberculosis, accounting for 1% of all forms of tuberculosis. Its prevalence varies according to coinfection with HIV. Mortality varies between 17 and 40%. In the US, the prevalence is low compared to developing countries. This article aims to review the literature on pericarditis caused by tuberculosis (TBP), its prevalence in the US, clinical manifestations, diagnosis, and treatment. Among the most frequent clinical manifestations are dyspnea, fever, chest pain, and cough. TBP should be suspected in patients at high risk of exposure to tuberculosis. There are multiple lab tests for diagnosis, and its primary treatment is triple therapy with isoniazid, rifampin, and streptomycin or ethambutol. In case of persistent elevation of systemic venous pressure, surgical intervention is indicated. The clinical presentation was found to be variable.
{"title":"Constrictive Pericarditis Secondary to Tuberculosis Infection: Literature Review","authors":"Maria Isabel Gomez Coral","doi":"10.19080/jocct.2022.18.555976","DOIUrl":"https://doi.org/10.19080/jocct.2022.18.555976","url":null,"abstract":"Tuberculous pericarditis is produced by Mycobacterium tuberculosis, accounting for 1% of all forms of tuberculosis. Its prevalence varies according to coinfection with HIV. Mortality varies between 17 and 40%. In the US, the prevalence is low compared to developing countries. This article aims to review the literature on pericarditis caused by tuberculosis (TBP), its prevalence in the US, clinical manifestations, diagnosis, and treatment. Among the most frequent clinical manifestations are dyspnea, fever, chest pain, and cough. TBP should be suspected in patients at high risk of exposure to tuberculosis. There are multiple lab tests for diagnosis, and its primary treatment is triple therapy with isoniazid, rifampin, and streptomycin or ethambutol. In case of persistent elevation of systemic venous pressure, surgical intervention is indicated. The clinical presentation was found to be variable.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128893075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-07DOI: 10.19080/jocct.2022.17.555975
E. Boubacar Ba
Active bleeding after cardiac surgery is defined as blood loss > 1.5 ml / kg / h for 6 consecutive hours within the first 24 hours or in case of re-operation for haemostasis within the first 12 hours postoperatively. The aim of our work was to assess the incidence and risk factors for the occurrence of active bleeding in postoperative valve surgery with extracorporeal circulation.
心脏手术后活动性出血定义为术后24小时内连续6小时失血量> 1.5 ml / kg / h或术后12小时内再次手术止血。我们的研究目的是评估体外循环瓣膜手术后活动性出血的发生率和危险因素。
{"title":"Active Bleeding after Valve Surgery under Extracorporeal Circulation: Incidence and Risk Factors? Prospective Observational Study on 59 Patients in a West African Country","authors":"E. Boubacar Ba","doi":"10.19080/jocct.2022.17.555975","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555975","url":null,"abstract":"Active bleeding after cardiac surgery is defined as blood loss > 1.5 ml / kg / h for 6 consecutive hours within the first 24 hours or in case of re-operation for haemostasis within the first 12 hours postoperatively. The aim of our work was to assess the incidence and risk factors for the occurrence of active bleeding in postoperative valve surgery with extracorporeal circulation.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"486 ","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134034930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-01DOI: 10.19080/jocct.2022.17.555974
I. Tlohi
Isolated chylopericardium due to mediastinal cystic lymphangioma is a rare entity. We report a case of asymptomatic chylopericardium in an 18 years old female with no history of trauma, thoracic surgery, malignancy, infection, or tuberculosis sand who presented with cardiomegaly noticed on chest x-ray before surgery of mandibular subluxation. Echocardiography showed a large number of pericardial effusions and pericardiocentesis yielded 1.25 L of milky-colored fluid which showed a triglyceride level of 4.82 g/L and cholesterol of 0.29 g/L with a cholesterol to triglyceride ratio of <1, characteristic of the chylous fluid. Chest computed tomography showed a huge mediastinal cystic lymphangioma. The patient successfully responded to continuous pericardial drainage and a medium-chain triglyceride diet then she was referred to the thoracic department for surgery. This type of case risks being misdiagnosed as tuberculosis, especially in countries where tuberculosis is endemic. Therefore, assessing pericardial fluid for chyle is crucial.
{"title":"Chylopericardium In a Young Woman Revealing A Mediastinal Cystic Lymphangioma: A Case Report","authors":"I. Tlohi","doi":"10.19080/jocct.2022.17.555974","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555974","url":null,"abstract":"Isolated chylopericardium due to mediastinal cystic lymphangioma is a rare entity. We report a case of asymptomatic chylopericardium in an 18 years old female with no history of trauma, thoracic surgery, malignancy, infection, or tuberculosis sand who presented with cardiomegaly noticed on chest x-ray before surgery of mandibular subluxation. Echocardiography showed a large number of pericardial effusions and pericardiocentesis yielded 1.25 L of milky-colored fluid which showed a triglyceride level of 4.82 g/L and cholesterol of 0.29 g/L with a cholesterol to triglyceride ratio of <1, characteristic of the chylous fluid. Chest computed tomography showed a huge mediastinal cystic lymphangioma. The patient successfully responded to continuous pericardial drainage and a medium-chain triglyceride diet then she was referred to the thoracic department for surgery. This type of case risks being misdiagnosed as tuberculosis, especially in countries where tuberculosis is endemic. Therefore, assessing pericardial fluid for chyle is crucial.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"67 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134000782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-30DOI: 10.19080/jocct.2022.17.555973
N. Mahoungou-Mackonia
HIT results from the development of F4P-specific IgG antibodies. It usually begins 5-14 days after initiation of heparin therapy with a drop in platelet count of more than 50% from a pretreatment value, associated in one in two patients with venous and/or arterial thrombotic complications. This is a rarer problem that occurs in 1-5% with UFH and 0.1-0.2% with LMWH and requires prompt management. Forty-seven-year-old patient, alcoholic at 3g/d for 10 years, hospitalized for APO complicating an ethylic CMD, LVEF 33% in tachy ACFA at 150batt/min. The patient was treated with furosemide and risordan. Injectable Cordarone was administered and LMWH in curative dose for 7 days. The evolution was marked by a resumption of sinus rhythm, disappearance of crepitus rales, after one week, but an installation of thrombenia at 22000/mm3, a pulmonary embolism, left popliteal DVT and thrombosis of the iliac and then left femoral arteries. The diagnosis of HIT type 2 was confirmed by the presence of anti-PF4 antibodies in association with the platelet activation test. LMWH was stopped, the patient received Fondaparinux 7.5mg/d until platelets normalized after 10 days and then substituted with rivaroxaban for 6 months after clinical improvement and normalization of arteriovenous Doppler ultrasound and chest angioscan.
{"title":"Heparin-Induced Venous and Arterial Thromboembolic Disease: Case Report and Literature Data","authors":"N. Mahoungou-Mackonia","doi":"10.19080/jocct.2022.17.555973","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555973","url":null,"abstract":"HIT results from the development of F4P-specific IgG antibodies. It usually begins 5-14 days after initiation of heparin therapy with a drop in platelet count of more than 50% from a pretreatment value, associated in one in two patients with venous and/or arterial thrombotic complications. This is a rarer problem that occurs in 1-5% with UFH and 0.1-0.2% with LMWH and requires prompt management. Forty-seven-year-old patient, alcoholic at 3g/d for 10 years, hospitalized for APO complicating an ethylic CMD, LVEF 33% in tachy ACFA at 150batt/min. The patient was treated with furosemide and risordan. Injectable Cordarone was administered and LMWH in curative dose for 7 days. The evolution was marked by a resumption of sinus rhythm, disappearance of crepitus rales, after one week, but an installation of thrombenia at 22000/mm3, a pulmonary embolism, left popliteal DVT and thrombosis of the iliac and then left femoral arteries. The diagnosis of HIT type 2 was confirmed by the presence of anti-PF4 antibodies in association with the platelet activation test. LMWH was stopped, the patient received Fondaparinux 7.5mg/d until platelets normalized after 10 days and then substituted with rivaroxaban for 6 months after clinical improvement and normalization of arteriovenous Doppler ultrasound and chest angioscan.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131857044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-08DOI: 10.19080/jocct.2022.17.555972
M. Tushar
A 50-year-old man with no prior medical history went to the emergency department complaining of persistent palpitations, pressure in his chest, and shortness of breath with an EKG that revealed atrial fibrillation with aberrancy. Patient became hemodynamically unstable and was cardiovert. Post cardioversion EKG showed diffuse ST depressions and he was sent to the cath lab, The patient’s post-catheterization ekg displayed a short PR interval and a delta wave compatible with Wolff Parkinson White syndrome. Patient was treated with postero-septal catheter ablation. After his symptoms subsided, the patient was sent home.
{"title":"Catheter Ablation of The Posterior-Septal Accessory Pathway in Patients with Wolf-Parkinson-White Syndrome Initially Present in Aberrant Atrial Fibrillation","authors":"M. Tushar","doi":"10.19080/jocct.2022.17.555972","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555972","url":null,"abstract":"A 50-year-old man with no prior medical history went to the emergency department complaining of persistent palpitations, pressure in his chest, and shortness of breath with an EKG that revealed atrial fibrillation with aberrancy. Patient became hemodynamically unstable and was cardiovert. Post cardioversion EKG showed diffuse ST depressions and he was sent to the cath lab, The patient’s post-catheterization ekg displayed a short PR interval and a delta wave compatible with Wolff Parkinson White syndrome. Patient was treated with postero-septal catheter ablation. After his symptoms subsided, the patient was sent home.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128822167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-07DOI: 10.19080/jocct.2022.17.555971
K. Roy
Higher mortality rates are linked to COVID-19 cardiovascular problems. Cardiac damage may result from a variety of factors, including combinations of cytokine storm, myocarditis, extremely high levels of physical and mental stress, ischemic injury, hyper-coagulopathy, right heart strain, and corpulmonale. Prognostic information is provided by echocardiography, c-TN, D-dimer, and NT-proBNP values. There is no particular therapy for COVID-19-related cardiac damage other from percutaneous coronary intervention for STEMI, and care is mostly supportive. It remains to be known if antiviral treatments given early in the course of the illness would stop the severe illness and cardiovascular consequences linked to COVID-19.SAIDs: Non-steroidal Anti-inflammatory Drugs; NO: Nitric Oxide; cGMP: cyclic Guanosine Monophosphate; LDL: Low-density Lipoprotein
{"title":"Cardiovascular Manifestations of COVID-19: An Update","authors":"K. Roy","doi":"10.19080/jocct.2022.17.555971","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555971","url":null,"abstract":"Higher mortality rates are linked to COVID-19 cardiovascular problems. Cardiac damage may result from a variety of factors, including combinations of cytokine storm, myocarditis, extremely high levels of physical and mental stress, ischemic injury, hyper-coagulopathy, right heart strain, and corpulmonale. Prognostic information is provided by echocardiography, c-TN, D-dimer, and NT-proBNP values. There is no particular therapy for COVID-19-related cardiac damage other from percutaneous coronary intervention for STEMI, and care is mostly supportive. It remains to be known if antiviral treatments given early in the course of the illness would stop the severe illness and cardiovascular consequences linked to COVID-19.SAIDs: Non-steroidal Anti-inflammatory Drugs; NO: Nitric Oxide; cGMP: cyclic Guanosine Monophosphate; LDL: Low-density Lipoprotein","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116859257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-22DOI: 10.19080/jocct.2022.17.555970
G. B. Benitez Lopez
{"title":"Heart Failure Management, including Recently Approved Therapeutic Options: An Overview","authors":"G. B. Benitez Lopez","doi":"10.19080/jocct.2022.17.555970","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555970","url":null,"abstract":"","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115256844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-09DOI: 10.19080/jocct.2022.17.555969
Guillermo Andrés Moreno Cortes
Social determinants of health interfere significantly in the health-disease process. This article examines the impact of these determinants on the main pathologies addressed by the internist and the family doctor in medical care. The World Health Organization defines social determinants of health (SDH) as the circumstances in which people are born, grow, work, live and age, including the broader set of forces and systems that influence conditions of daily life. These forces and systems include economic policies and systems, development programs, social norms and policies, and political systems. The above conditions can be very different for various subgroups of a population and can lead to differences in health outcomes. It may be unavoidable that some of these conditions are different, which is considered inequalities. These social determinants influence and modify the development and course of the disease. In the pathologies exposed in this review, we found that adequate management involves a sizeable non-pharmacological component that refers to intervention in eating habits, healthy living, management of traditional cardiovascular risk factors, and monitoring disease activity. In support of the evidence, we review several meta-analyses of observational studies that allow us to infer what is the significant impact of the social determinants of health in the control or exacerbation of the pathologies described and how we can positively interfere in their evolution and outcome of disease through increasingly effective comprehensive interventions according to the current evidence described.
{"title":"Social Determinants of Health on Cardiovascular Disease Prevention in Special Populations: An Overview","authors":"Guillermo Andrés Moreno Cortes","doi":"10.19080/jocct.2022.17.555969","DOIUrl":"https://doi.org/10.19080/jocct.2022.17.555969","url":null,"abstract":"Social determinants of health interfere significantly in the health-disease process. This article examines the impact of these determinants on the main pathologies addressed by the internist and the family doctor in medical care. The World Health Organization defines social determinants of health (SDH) as the circumstances in which people are born, grow, work, live and age, including the broader set of forces and systems that influence conditions of daily life. These forces and systems include economic policies and systems, development programs, social norms and policies, and political systems. The above conditions can be very different for various subgroups of a population and can lead to differences in health outcomes. It may be unavoidable that some of these conditions are different, which is considered inequalities. These social determinants influence and modify the development and course of the disease. In the pathologies exposed in this review, we found that adequate management involves a sizeable non-pharmacological component that refers to intervention in eating habits, healthy living, management of traditional cardiovascular risk factors, and monitoring disease activity. In support of the evidence, we review several meta-analyses of observational studies that allow us to infer what is the significant impact of the social determinants of health in the control or exacerbation of the pathologies described and how we can positively interfere in their evolution and outcome of disease through increasingly effective comprehensive interventions according to the current evidence described.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126567998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-04-27DOI: 10.19080/jocct.2020.16.555932
Fabricio Sarmento Vassallo
Introduction/Objective: Ablation of premature ventricular complexes a challenge in routine electrophysiology because results, depend on factors such as location, tools and technologies used. Aim of study was analyze exclusive use of pace-mapping technique with module of Score Map Software of Ensite Velocity/Precision and compare with success procedure, 7- and 30-days post-ablation. Methods/Results: Retrospectively analyzed 50 procedures in 47 symptomatic patients between January 2018 and February 2020. Ablation with irrigated tip catheter, power 40Watts, pump flow 30ml/min. Mapping with Duodecapolar in 40(80%) and HDGrid catheter in 10(20%). Female was 25 (53.19%), mean age 53.5years (19-78), hypertension 27 (57.45%), 7 (14.91%) coronary disease, 4 (8.51%) myocarditis, 2 (4.26%) Diabetes and 2 (4.26%) patients with an implanted defibrillator. Mean ejection fraction 63.17%. Average radiofrequency time was 580.58 seconds and mean XRay time 7.74min. Median SM was 93.92% and only 8 (16%) ablations were considered unsuccessful due to maintenance of extrasystoles or do not show a marked reduction on PVC at the end of the procedure. At 7- and 30-days follow up 9 (18%) and 7 (14%) patients had unsuccessful ablation. All patients had a Score <95%, underwent ablation with conscious sedation, majority female, most PVCs located in left ventricle and had more extensive ablation. Conclusion: Score Map is useful as exclusive technique for ablation of premature ventricular complexes with very good acute success and low complications. Score Map more than 95% had high success. Failure is related to conscious sedation, female gender, left ventricle ablation and longer radiofrequency time.
{"title":"Catheter Ablation of Premature Ventricular Complexes Exclusively by a Pace-Mapping Software Technique: Feasibility of a Registry Study","authors":"Fabricio Sarmento Vassallo","doi":"10.19080/jocct.2020.16.555932","DOIUrl":"https://doi.org/10.19080/jocct.2020.16.555932","url":null,"abstract":"Introduction/Objective: Ablation of premature ventricular complexes a challenge in routine electrophysiology because results, depend on factors such as location, tools and technologies used. Aim of study was analyze exclusive use of pace-mapping technique with module of Score Map Software of Ensite Velocity/Precision and compare with success procedure, 7- and 30-days post-ablation. Methods/Results: Retrospectively analyzed 50 procedures in 47 symptomatic patients between January 2018 and February 2020. Ablation with irrigated tip catheter, power 40Watts, pump flow 30ml/min. Mapping with Duodecapolar in 40(80%) and HDGrid catheter in 10(20%). Female was 25 (53.19%), mean age 53.5years (19-78), hypertension 27 (57.45%), 7 (14.91%) coronary disease, 4 (8.51%) myocarditis, 2 (4.26%) Diabetes and 2 (4.26%) patients with an implanted defibrillator. Mean ejection fraction 63.17%. Average radiofrequency time was 580.58 seconds and mean XRay time 7.74min. Median SM was 93.92% and only 8 (16%) ablations were considered unsuccessful due to maintenance of extrasystoles or do not show a marked reduction on PVC at the end of the procedure. At 7- and 30-days follow up 9 (18%) and 7 (14%) patients had unsuccessful ablation. All patients had a Score <95%, underwent ablation with conscious sedation, majority female, most PVCs located in left ventricle and had more extensive ablation. Conclusion: Score Map is useful as exclusive technique for ablation of premature ventricular complexes with very good acute success and low complications. Score Map more than 95% had high success. Failure is related to conscious sedation, female gender, left ventricle ablation and longer radiofrequency time.","PeriodicalId":447476,"journal":{"name":"Journal of Cardiology & Cardiovascular Therapy","volume":"142 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141209792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：